Breakthrough: New Pulmonary Fibrosis Treatment BMS-986278 Demonstrates Significant Lung Function Preservation in Phase 2 Trial

Bristol Myers Squibb just unveiled compelling Phase 2 results for BMS-986278, an experimental oral LPA1 antagonist targeting progressive pulmonary fibrosis—and the numbers are striking. When administered at 60 mg twice daily for 26 weeks, the drug achieved a 69% relative reduction in lung function decline compared to placebo, measured by percent predicted forced vital capacity (ppFVC).

The Clinical Evidence Speaks

The trial data tells an important story for patients facing this devastating disease. In the progressive pulmonary fibrosis cohort, the 60 mg dose slowed the rate of ppFVC decline from 4.2% (placebo) to just 1.3% annually—a meaningful difference for individuals living with progressive fibrosing lung disease. Even more compelling: a 74% relative reduction emerged when analyzing all available data regardless of dose adjustments.

The 30 mg dose also showed promise with a 42% relative reduction in the while-on-treatment analysis, though the higher dose demonstrated superior efficacy.

Consistent Efficacy Across Patient Subgroups

What makes these BMS-986278 results particularly promising is their consistency. The treatment effect remained robust whether patients received background antifibrotic therapy or not—approximately 38% of participants used standard antifibrotic drugs alongside the investigational agent. Similarly, the benefit held regardless of whether patients had usual interstitial pneumonia (UIP) pattern, suggesting broad applicability.

Safety Profile: A Critical Advantage

Beyond efficacy, tolerability matters enormously. BMS-986278 demonstrated a favorable safety profile: adverse event rates were comparable to placebo (67% vs. 78% in placebo arm), while treatment discontinuation rates due to adverse events were dramatically lower—only 0% in the 60 mg group versus 15% in placebo.

The most common side effects (diarrhea, COVID-19, cough, dyspnea) occurred at manageable frequencies, with serious adverse events notably lower in the BMS-986278 groups (12% at 60 mg versus 32% in placebo).

Mechanism and Context

BMS-986278 targets lysophosphatidic acid receptor 1 (LPA1) inhibition—addressing a recognized pathogenic pathway in pulmonary fibrosis. Preclinical evidence suggests LPA1 antagonism may mitigate lung injury and fibrotic progression, positioning this approach as a potential first-in-class option.

What Happens Next

These Phase 2 progressive pulmonary fibrosis findings, combined with previously reported idiopathic pulmonary fibrosis data (showing 62% relative reduction), have paved the way for the global Phase 3 ALOFT program (An LPA1 antagonist fOr pulmonary Fibrosis Trial). Both IPF and PPF cohorts are advancing to late-stage evaluation.

Why This Matters

Pulmonary fibrosis remains a serious challenge—median survival of 3–5 years post-diagnosis, 5-year survival near 45% for IPF. Most patients experience progressive breathlessness, physical impairment, and require continuous supplemental oxygen. Innovation has stalled, with few new therapies approved in nearly a decade. BMS-986278 represents a potential turning point for thousands of patients globally living with this condition.

The Phase 2 data will be formally presented at the European Respiratory Society 2023 International Congress (September 9-13, Milan), with enrollment now shifting to Phase 3 evaluation. For the pulmonary fibrosis community, the BMS-986278 trajectory offers genuine optimism.